Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
Luveltamab tazevibulin
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05870748II/IIIPlatinum resistant FOLR+ high grade serous ovarian cancer with prior bevacizumab (Phase III)REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)AZ, CA, DC, FL, MD, MA, MN, NE, NM, NY, OH, OK, OR, PA, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Luveltamab tazevibulinSTRO-002, anti-folate receptor-alpha antibody drug conjugate STRO-002ADC: anti-FRalpha + microtubule destabilizer (SC209)Clinical Trials
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT05200364IPlatinum resistant or refractory high grade serous ovarian cancerA Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)FL, PA, TN, VA, WIView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Luveltamab tazevibulinSTRO-002, anti-folate receptor-alpha antibody drug conjugate STRO-002ADC: anti-FRalpha + microtubule destabilizer (SC209)Clinical Trials
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.